Nerve Ultrasound of Peripheral Nerves in Patients Treated with Immune Checkpoint Inhibitors
暂无分享,去创建一个
A. Grimm | C. Kronlage | M. Renovanz | J. Stahl | N. Winter | K. Kneer | P. Bombach | Cornelius Kronlage
[1] S. Brandner,et al. 197 Checkpoint inhibitor associated neuritis a novel pathological entity , 2022, Journal of Neurology Neurosurgery & Psychiatry.
[2] Yan Li,et al. Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases , 2021, BioMed research international.
[3] R. Lewis,et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision , 2021, European journal of neurology.
[4] R. Lewis,et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision , 2021, Journal of the peripheral nervous system : JPNS.
[5] A. Grimm,et al. Nerve Ultrasound as Helpful Tool in Polyneuropathies , 2021, Diagnostics.
[6] Julian Schardt. Der Einsatz von Immuncheckpoint-Inhibitoren im onkologischen Alltag , 2020, Zeitschrift für Rheumatologie.
[7] M. Payne,et al. Toxicities associated with checkpoint inhibitors—an overview , 2019, Rheumatology.
[8] Peter C Pan,et al. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition , 2019, Current Oncology Reports.
[9] R. Gutzmer,et al. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook , 2019, Journal of clinical medicine.
[10] L. Deangelis,et al. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy , 2019, Clinical Neurophysiology.
[11] A. Kartolo,et al. Predictors of immunotherapy-induced immune-related adverse events. , 2018, Current oncology.
[12] Wei-min Li,et al. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials , 2018, Journal of Cancer Research and Clinical Oncology.
[13] S. Attarian,et al. Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review , 2018, Muscle & nerve.
[14] Y. Nakatsuji,et al. Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barré syndrome , 2018, Journal of the Neurological Sciences.
[15] H. Axer,et al. A look inside the nerve – Morphology of nerve fascicles in healthy controls and patients with polyneuropathy , 2017, Clinical Neurophysiology.
[16] M. Suarez‐Almazor,et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.
[17] K. Kerr,et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] M. Fujimoto,et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. , 2016, Japanese journal of clinical oncology.
[19] Z. Fang,et al. PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis , 2016, PloS one.
[20] P. Saiag,et al. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. , 2016, The New England journal of medicine.
[21] F. Hodi,et al. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. , 2015, The New England journal of medicine.
[22] R. Dummer,et al. Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab , 2013, Cancer.
[23] A. Tarhini. Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management , 2013, Scientifica.
[24] R. Strowd,et al. Neurologic complications of immune checkpoint inhibitors , 2021, Neuro-Oncology for the Clinical Neurologist.
[25] Ho Lam Chan,et al. Immune checkpoint inhibitors: basics and challenges. , 2019, Current medicinal chemistry.